GlaxoSmithKline announces positive results from Relvar Ellipta study

GlaxoSmithKline and Innovia announced positive headline results from their Salford lung study of Relvar Ellipta in the treatment of chronic obstructive pulmonary disease (COPD).

The study showed Relvar Ellipta achieved a superior reduction in exacerbations versus usual care in patients with COPD in an everyday clinical practice setting.

Eric Dube, senior vice president and head of GSK’s Global Respiratory Franchise, said: “The Salford Lung Study COPD results support the effectiveness of Relvar. As we move beyond the headline results, we will learn so much more about the medicine and disease management.

“We believe the results could transform understanding of how patients in everyday clinical practice respond to COPD treatments.”

COPD is a disease of the lungs that includes chronic bronchitis, emphysema or both. It is characterised by obstruction to airflow that interferes with normal breathing.

At 1227 BST, Glaxo shares were up 0.6% to 1,446p.